New possibilities for the treatment of oncopathologies
Sotorasib has been shown to be effective in the treatment of colorectal cancer and pancreatic cancer with the KRAS G12C mutation in early clinical trials.
The KRAS mutation is one of the most common in colorectal and pancreatic cancers. However, despite this, there is still no targeted drug that works specifically with these pathological variants.
Sotorasib is one of the first inhibitors of this mutation. The CodeBreaK100 Phase I/II trials included 38 patients with pancreatic cancer and 62 patients with colon cancer. Disease control (partial response or stabilization based on the results of instrumental examination) was achieved in 84.3% of patients with pancreatic cancer and in 82.3% of patients with colorectal cancer.
The data obtained give reason to hope for the imminent emergence of a new treatment option for these patients.
You can learn more at this link and here.
We thank E.F. Satirova, head of the department of antitumor drug treatment, oncologist K+31 West, for the up-to-date information.
